Additionally, ALYREF has been shown to promote tumor growth and increase Ki-67 expression in tumor tissues, while NSUN6 inhibits pancreatic cancer cell proliferation and in vivo tumor growth (Meng Q. et al., 2024; Yang R. et al., 2021). Here, ALYREF is linked to pancreatic neoplasm.